Literature DB >> 24365642

The microenvironment in lymphomas--dissecting the complex crosstalk between tumor cells and 'by-stander' cells.

Richard Rosenquist1, Frédéric Davi2, Paolo Ghia3.   

Abstract

In lymphomas, it is increasingly apparent that the microenvironment is an essential player not only for lymphoma pathogenesis but also for disease progression and therapy resistance. In recent years, we have begun to understand the complex crosstalk between the neoplastic cells and other immune cells, such as T and NK cells, and stromal cells, as well as the signaling pathways that become aberrantly activated through this dialogue (e.g. B-cell receptor, Toll-like receptor and NF-?B signaling). In this series of reviews, the intricate interplay between lymphoma cells and 'by-stander' cells will be illustrated in representative lymphoma entities, namely Hodgkin lymphomas, follicular lymphomas, marginal-zone lymphomas, chronic lymphocytic leukemia, and T-cell lymphomas, where the crucial role played by the microenvironment has become particularly evident. Furthermore, important clues to the pathobiology of lymphomas have emerged from (i) the recognition of pre-malignant conditions, such as monoclonal B-cell lymphocytosis or in situ lymphomas, (ii) the identification of microbial and/or auto-antigens that are linked to particular entities, as well as (iii) the established increased risk of lymphomas in certain autoimmune/inflammatory conditions, all critical aspects that will be further elaborated in this thematic issue. Our increasing knowledge of these interactions and associations has finally allowed us to design targeted or immune-mediated strategies to interfere with the lymphoma microenvironment, thereby opening promising therapeutic avenues on the road to cure for these yet incurable diseases.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24365642     DOI: 10.1016/j.semcancer.2013.12.002

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  5 in total

1.  First-line combination of GELOX followed by radiation therapy for patients with stage IE/IIE ENKTL: An updated analysis with long-term follow-up.

Authors:  Liang Wang; Zhi-Hui Wang; Xiao-Qin Chen; Ke-Feng Wang; Hui-Qiang Huang; Zhong-Jun Xia
Journal:  Oncol Lett       Date:  2015-06-05       Impact factor: 2.967

2.  Integrin αvβ3 acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells.

Authors:  Florencia Cayrol; María Celeste Díaz Flaqué; Tharu Fernando; Shao Ning Yang; Helena Andrea Sterle; Marcela Bolontrade; Mariana Amorós; Blanca Isse; Ricardo Norberto Farías; Haelee Ahn; Ye F Tian; Fabrizio Tabbò; Ankur Singh; Giorgio Inghirami; Leandro Cerchietti; Graciela Alicia Cremaschi
Journal:  Blood       Date:  2014-12-08       Impact factor: 22.113

3.  On the representation of cells in bone marrow pathology by a scalar field: propagation through serial sections, co-localization and spatial interaction analysis.

Authors:  Cleo-Aron Weis; Benedict Walter Grießmann; Christoph Scharff; Caecilia Detzner; Eva Pfister; Alexander Marx; Frank Gerrit Zoellner
Journal:  Diagn Pathol       Date:  2015-09-02       Impact factor: 2.644

4.  Clonal evolution is a prognostic factor for the clinical progression of monoclonal B-cell lymphocytosis.

Authors:  I V Kostopoulos; G Paterakis; D Pavlidis; E Kastritis; E Terpos; O E Tsitsilonis; S I Papadhimitriou
Journal:  Blood Cancer J       Date:  2017-08-25       Impact factor: 11.037

5.  IL-10 induces the development of immunosuppressive CD14(+)HLA-DR(low/-) monocytes in B-cell non-Hodgkin lymphoma.

Authors:  B Xiu; Y Lin; D M Grote; S C Ziesmer; M P Gustafson; M L Maas; Z Zhang; A B Dietz; L F Porrata; A J Novak; A-B Liang; Z-Z Yang; S M Ansell
Journal:  Blood Cancer J       Date:  2015-07-31       Impact factor: 11.037

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.